Comparing the effectiveness of morning and evening dosing of tofacitinib in inflammatory arthritis
- Conditions
- Inflammatory arthritis (rheumatoid arthritis and psoriatic arthritis)Musculoskeletal DiseasesRheumatoid arthritis, unspecified, Other psoriatic arthropathies
- Registration Number
- ISRCTN68663074
- Lead Sponsor
- Erasmus MC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 84
Current inclusion criteria as of 21/11/2023:
1. Age =18 years
2. Diagnosed with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to respectively the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 criteria for RA and ClASsification for Psoriatic ARthritis (CASPAR) criteria
3. Active disease, defined as a Disease Activity Score (DAS) >2.4 or Disease Activity in PSoriatic Arthritis (DAPSA) score >14
Previous inclusion criteria:
1. Age =18 years
2. Diagnosed with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to respectively the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 criteria for RA and ClASsification for Psoriatic ARthritis (CASPAR) criteria
3. Active disease, defined as a Disease Activity Score (DAS) >2.4 or Disease Activity in PSoriatic Arthritis (DAPSA) score >14
4. Biological disease-modifying antirheumatic drug (bDMARD) usage <3
1. Current or previous treatment with a targeted synthetic (ts)DMARD
2. Prednisone (or equivalent) at a dose of >7.5 mg
3. (Relative) contraindications for the study medication
4. Work in shifts
5. Not being able to understand, speak and write in Dutch
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease activity measured with the Routine Assessment of Patient Index Data 3 (RAPID3) at 3 months
- Secondary Outcome Measures
Name Time Method